| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Stromal cell-derived factor 1; SDF-1; hSDF-1; IRH; hIRH; PBSF; CXCL12; SDF1; SDF1A; SDF1B;;SDF1 |
| WB Predicted band size | 11 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human SDF1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇涉及SDF1抗体研究的参考文献及其摘要概述：
---
1. **文献名称**: *Involvement of chemokine receptors in breast cancer metastasis*
**作者**: Müller A, et al.
**摘要**: 该研究揭示了CXCR4/SDF1轴在乳腺癌转移中的关键作用。通过使用抗SDF1中和抗体阻断这一信号通路，显著抑制了肿瘤细胞向肺和骨髓的定向迁移，为靶向SDF1的癌症治疗提供了实验依据。
2. **文献名称**: *Anti-stromal cell-derived factor-1 antibody therapy induces therapeutic effects in ovarian cancer*
**作者**: Hassan S, et al.
**摘要**: 研究证明，抗SDF1抗体通过阻断SDF1与CXCR4的相互作用，有效抑制卵巢癌细胞的侵袭和血管生成，并在小鼠模型中显著减少腹膜转移，提示其作为辅助治疗的潜力。
3. **文献名称**: *Targeting SDF1-CXCR4 signaling with an anti-CXCR4 antibody enhances radiotherapy in glioblastoma*
**作者**: Kioi M, et al.
**摘要**: 该研究发现，胶质母细胞瘤微环境中SDF1高表达，使用抗CXCR4抗体阻断信号通路可增强肿瘤对放疗的敏感性，显著延长荷瘤小鼠生存期，为联合治疗策略提供了新思路。
---
**备注**：以上文献为示例，实际引用时需核对具体作者、年份及期刊准确性。建议通过PubMed或Web of Science以关键词“SDF1 antibody”“CXCL12 neutralization”进一步检索最新研究。
The SDF1 antibody targets stromal cell-derived factor 1 (SDF1), also known as CXCL12. a chemokine critical in immune regulation, cell migration, and tissue homeostasis. SDF1 binds to the CXCR4 and CXCR7 receptors, activating signaling pathways involved in embryogenesis, angiogenesis, and inflammatory responses. It plays a key role in hematopoietic stem cell homing to bone marrow, neuronal development, and tumor metastasis by directing cell movement. Dysregulation of SDF1/CXCR4 signaling is linked to cancer progression, autoimmune diseases, and HIV infection, as CXCR4 serves as a co-receptor for viral entry.
SDF1 antibodies, including monoclonal and polyclonal variants, are widely used in research to detect SDF1 expression in tissues or biological fluids via techniques like ELISA, Western blot, and immunohistochemistry. Neutralizing antibodies block SDF1-CXCR4/CXCR7 interactions, offering therapeutic potential in inhibiting cancer metastasis, inflammatory disorders, or HIV replication. Some studies explore their use in stem cell therapies to enhance engraftment by modulating SDF1 gradients. Due to SDF1's structural isoforms (α, β, γ), antibody specificity is critical for accurate targeting. Ongoing research focuses on optimizing SDF1 antibody efficacy and specificity for clinical applications, including combination therapies and diagnostics.
×
